GlobeNewswire Inc | Nov 12, 2020 08:00AM EST

November 12, 2020

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- AdaptimmuneTherapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, willhosta virtualInvestor Dayon November20, 2020at 8AM EST/ 1PM GMT.Alink to register is available HERE and further details are on the Investor Relations tab of theAdaptimmunewebsite.

The Company plans to showcase the market potential for its SPEAR T-cell portfolio as well as provide details about its early stage pipeline with multiple cell therapies beyond its current autologous TCR T-cell products. Presentations will be given byAdaptimmunesSenior Leadership Team in addition to Dr. Dejka Araujo from the Department of Sarcoma Medical Oncology, Division of Cancer Medicine of the MD Anderson Cancer Center.

AboutAdaptimmuneAdaptimmuneis a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Companys unique SPEAR(Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.

Forward-Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory andcommercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Media Relations:

Sbastien Desprez VP, Communications and Investor RelationsT: +44 1235 430 583M: +44 7718 453 176Sebastien.Desprez@adaptimmune.com

Investor Relations:

Juli P. Miller, Ph.D. Senior Director, Investor RelationsT: +1 215 825 9310M: +1 215 460 8920Juli.Miller@adaptimmune.com